Project description
Parkinson’s disease modifying strategy using iron chelation
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. It is associated with iron excess in the substantia nigra, exposing dopaminergic neurons to high levels of oxidative stress resulting from mitochondrial and dopamine metabolism disorders. Previous preclinical and pilot clinical studies demonstrated the effectiveness of a novel iron chelation therapy with deferiprone (DFP) in inducing neuroprotection in PD cell models, as well as slowing the disease progression in mouse models and early-stage PD patients. The objective of the EU-funded FAIR-PARK-II project is to conduct a parallel-group, randomised, placebo-controlled, clinical trial to demonstrate that DFP can slow the progression of disability in de novo PD patients, thereby establishing iron chelation as a disease-modifying treatment in neurodegeneration.
Objective
Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinical studies demonstrated that novel iron chelation therapy with the prototypic drug deferiprone (DFP) (i) induces neuroprotection in cell models of PD via a powerful antioxidant effect, (ii) reduces regional siderosis of the brain, (iii) reduces motor handicap via inhibition of catechol-o-methyl transferase, and (iv) slows the progression of motor handicap in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model and in early PD patients. This project now seeks to demonstrate that conservative iron chelation therapy with moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parkinson’s Disease Rating Scale to identify disease-modifying and symptomatic effects. The secondary efficacy criterion will be the change in score between baseline and 40 weeks (i.e. probing the disease-modifying effect only). Potential surrogate radiological and biological biomarkers, health economics and societal impacts will be assessed. 17 national, European and international research and innovation activities will be linked with the project. The study results should prompt academic and industrial research on iron chelation as a disease-modifying treatment in neurodegenerative diseases.
Fields of science
- natural sciencescomputer and information sciencesdatabases
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesbasic medicineneurologyparkinson
- social scienceseconomics and businesseconomicshealth economics
- natural sciencesphysical sciencesacousticsultrasound
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
59037 Lille
France
See on map
Participants (20)
75654 Paris
See on map
75014 Paris
See on map
75015 PARIS
See on map
Participation ended
M9L 1T9 Toronto
See on map
1649 028 Lisboa
See on map
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
NE1 7RU Newcastle Upon Tyne
See on map
Participation ended
72074 Tuebingen
See on map
6020 Innsbruck
See on map
116 36 Praha 1
See on map
Participation ended
6525 XZ Nijmegen
See on map
35037 Marburg
See on map
75006 Paris
See on map
89081 Ulm
See on map
Participation ended
24118 Kiel
See on map
23562 Lübeck
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
24118 Kiel
See on map
6525 GA Nijmegen
See on map
43122 Parma
See on map